Day: June 29, 2020

ENSPRYNG is Japan’s first and only approved therapy for both adults and children with neuromyelitis optica spectrum disorder (NMOSD)ENSPRYNG is the first and only approved therapy targeting the interleukin-6 (IL-6) receptor given subcutaneously every four weeksApproval is supported by data demonstrating ENSPRYNG’s robust efficacy, which was well-tolerated with a consistent safety profile, in a broad NMOSD population as a monotherapy and as an add-on therapyAsia has a high prevalence of NMOSD with limited treatment options             Basel, 29 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved ENSPRYNG® (satralizumab) for the prevention of relapses of neuromyelitis optica spectrum disorder (NMOSD), including NMO, for aquaporin-4 antibody (AQP4-IgG)...

Nasdaq OMX Copenhagen A/SCharlottenlund, den 29. juni 2020Meddelelse nr. 210Selskabsmeddelelse – indgåelse af market maker aftale

Foresight VCT plcChange to Director InformationIn accordance with Listing Rule 9.6.14, Foresight VCT plc announces the appointment of Gordon Humphries as an independent non-executive director of JPMorgan Smaller Companies Investment Trust PLC with effect from 1 July 2020.For further information please contact:Gary Fraser, Foresight Group:                            020 3667 8181

As previously announced, Icelandair Group is negotiating with its stakeholders in order to be able to initiate offering of new shares and complete a financial restructuring of the Company. The milestone for reaching agreements had been set today.Icelandair Group has to date achieved positive progress with many of its stakeholders. New long-term collective-bargaining agreements have been reached with the unions of pilots, cabin crew and mechanics.  Work on terms with the Icelandic Government, along with Íslandsbanki and Landsbankinn, regarding a government guaranteed credit facility is in progress. However, the credit facility will, among other things, be conditioned upon the Company receiving sufficient concessions from creditors and successful conclusion of the planned share offering.Icelandair Group has received positive feedback from...

Offer, buyback, cut-off price, pro rata and yield are presented in the table below:

Udbud, køb, skæringspris, pro rata og effektiv rente fremgår af nedenstående oversigt:

Bids, sales, stop-rates and prices are presented in the table below:      The sale will settle 1 July 2020.

Bud, salg, skæringsrenter og pris fremgår af nedenstående oversigt: Salget bliver afviklet den 1. juli 2020.

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.The following transactions have been executed during the period 22 – 26 June 2020:Henceforth, Coloplast owns 3,284,697 treasury B shares of DKK 1 equal to 1.52%...

Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. Programmet begyndte den 24. februar 2020 og forventes afsluttet den 24. august 2020.Aktietilbagekøbsprogrammet struktureres i henhold til bestemmelserne i artikel 5 i EU-Parlamentet og Rådets forordning nr. 596/2014 af 16. april 2014 (MAR) og forordning 2016/1052, også kaldet ”Safe Harbour” reglerne, med det formål at opfylde forpligtelser i henhold til aktieoptionsprogrammer eller andre aktieallokeringer til medarbejdere eller at gennemføre en kapitalnedsættelse i henhold til artikel 5(2)(a) og artikel 5(2)(c) i MAR.I perioden 22. – 26. juni 2020 er der foretaget følgende køb:Coloplast ejer herefter 3.284.697 egne B-aktier à DKK 1 svarende til 1,52% af selskabets samlede aktiekapital.Separat oversigt med transaktionsdata...